IMUXNasdaqPharmaceutical PreparationsFiscal year ends December 31
IMMUNIC, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$6.99+0.02 (+0.29%)
Close on Oct 19, 2026
- Market cap
- $297.17M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -58.2% | -40.5% | -1653.1% | |
| Return on assets | -53.5% | -37.7% | -299.4% | |
| Current ratio | 11.22 | 15.93 | 0.75 | |
| Diluted shares | 0M | 2M | 16M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Immunic generated $389.78M from operations and spent $938.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$389.78M
Used
$938.00K
Capital expenditure$938.00K100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$97.17M
- Cash generatingOperating cash flow above zero-$85.81M
- Return on assets improvedROA up on the prior year-185.1% → -237.8%
- Earnings backed by cashOperating cash flow above net income-$85.81M vs -$97.17M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.77 → 0.75
- No dilutionShare count did not rise10M → 16M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –